Fig. 6.

The effect of rCCL17 activation of CCR4 signaling pathway was reversed by administration of CCR4 inhibitor, C021 at 72 h after ICH. (A) WB bands of CCL17, CCR4, p-ERK1/2, ERK1/2, Nrf2, CD163, and actin; (B–F) quantitative analysis of CCL17, CCR4, p-ERK/ERK, Nrf2, and CD163 expression; (G) modified Garcia test; (H) forelimb placement test; (I) corner turn test. *p < 0.05 versus sham, @p < 0.05 versus ICH + vehicle, #p < 0.05 versus ICH + rCCL17, $p < 0.05 versus rCCL17 + DMSO. Mean ± SD, one-way ANOVA, Tukey test, n = 6/group. p-ERK1/2, phosphorylated extracellular regulated protein kinases 1/2; ERK1/2, extracellular regulated protein kinases1/2